منابع مشابه
New anti-inflammatory agents.
The pyrrole derivatives la, b and 2a, b were used as precursors for the preparation of N-substituted pyrrole derivatives 3a, b-9a, b and pyrrolo[2,3-d]pyrimidines 13-16. Also, all the newly prepared products were tested for anti-inflammatory activity as analogues to fenamates, and some of them revealed moderate anti-inflammatory activity compared to the standard drug indomethacin.
متن کاملNew therapeutic agents in diabetic nephropathy
Studies investigating diabetic nephropathy (DN) have mostly focused on interpreting the pathologic molecular mechanisms of DN, which may provide valuable tools for early diagnosis and prevention of disease onset and progression. Currently, there are few therapeutic drugs for DN, which mainly consist of antihypertensive and antiproteinuric measures that arise from strict renin-angiotensin-aldost...
متن کاملA study of the anti-diabetic agents of camel milk.
The number of people diagnosed with type 2 diabetes has risen steeply recently exhausting the ability of health care systems to deal with the epidemic. Seventy-five percent of people with diabetes live in low- and middle-income countries. The largest populations of diabetics are in China and India, with many of those people living in extreme pover...
متن کاملSmall molecule glucokinase activators as novel anti-diabetic agents.
The monomeric enzyme GK (glucokinase) has a low affinity for glucose and, quantitatively, is largely expressed in the liver and pancreatic beta-cells, playing a key 'glucose sensing' role to regulate hepatic glucose balance and insulin secretion. Mutations of GK in man can be inactivating, to cause a form of diabetes mellitus, or activating, to lower blood glucose levels. Recently, models of GK...
متن کاملAnti-vascular endothelial growth factor agents for diabetic maculopathy.
The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still underway. There are no established protocols on ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Korean Medical Association
سال: 2017
ISSN: 1975-8456,2093-5951
DOI: 10.5124/jkma.2017.60.12.992